Treatment of Candida glabrata Vaginal Infection

First-line Treatment Options

• The Infectious Diseases Society of America recommends topical intravaginal boric acid in a gelatin capsule, 600 mg daily for 14 days, as the first-line treatment for C. glabrata vulvovaginitis, especially when oral azoles are ineffective 1, 2, 3
• C. glabrata infections are considered "complicated" vulvovaginal candidiasis and require specific treatment approaches different from those used for C. albicans, according to the Clinical Infectious Diseases guidelines 1, 4

Alternative Treatment Options

• Nystatin intravaginal suppositories, 100,000 units daily for 14 days, can be used as an alternative treatment for C. glabrata infection, as suggested by the Clinical Infectious Diseases guidelines 1, 2, 3
• Topical 17% flucytosine cream alone or in combination with 3% AmB cream administered daily for 14 days is another option, though this is a weaker recommendation from the Clinical Infectious Diseases guidelines 1, 2, 3

Treatment Considerations

• C. glabrata often demonstrates resistance to azole antifungals, including fluconazole, making standard treatments for C. albicans ineffective, as reported in the Clinical Infectious Diseases journal 4
• Treatment should continue for the full 14-day course to ensure complete eradication of the infection, according to the Clinical Infectious Diseases guidelines 1, 2, 3

Diagnostic Confirmation

• Before initiating treatment, confirm the diagnosis through wet-mount preparation with saline and 10% potassium hydroxide to demonstrate yeast or hyphae, as recommended by the Clinical Infectious Diseases guidelines 5, 6
• Vaginal cultures should be obtained for those with negative microscopy findings to identify the specific Candida species, according to the Clinical Infectious Diseases guidelines 5, 6
• A normal vaginal pH (4.0-4.5) should be verified before starting treatment, as suggested by the Clinical Infectious Diseases guidelines 5, 6

Treatment Monitoring and Follow-up

• Patients should be instructed to return for follow-up visits if symptoms persist or recur after completing the treatment course, as recommended by the MMWR Recommendations and Reports 7
• Clinical response should be evaluated after completing the 14-day treatment regimen, according to the Clinical Infectious Diseases guidelines 1, 2, 3
• If symptoms persist despite appropriate therapy, consider alternative diagnoses or resistant infection, as suggested by the Clinical Infectious Diseases guidelines 1, 4

Special Considerations

• Oil-based creams and suppositories might weaken latex condoms and diaphragms, so patients should be advised about potential contraceptive failure, as recommended by the MMWR Recommendations and Reports 7
• Treatment approach should not differ based on HIV status, with identical response rates expected in both HIV-positive and HIV-negative women, according to the Clinical Infectious Diseases guidelines 4

Treatment of Vaginal Candida glabrata Infection

Diagnosis and Treatment

• The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, suggests that vaginal cultures are essential for proper identification of C. glabrata, as this organism doesn't form pseudohyphae or hyphae, making it difficult to recognize on microscopy 8, 9
• Non-fluconazole azole drugs can be used for 7-14 days as first-line therapy for non-albicans species, such as C. glabrata, according to the MMWR Recommendations and Reports 8
• The MMWR Recommendations and Reports advises against using fluconazole monotherapy for confirmed C. glabrata, as conventional antimycotic therapies are not as effective against non-albicans species compared to C. albicans 8, 9

Epidemiology

• C. glabrata and other non-albicans species are found in 10-20% of patients with recurrent vulvovaginal candidiasis, as stated in the MMWR Recommendations and Reports 8, 9

Treatment of Candida glabrata Vaginal Yeast Infection

Diagnosis and Treatment Recommendations

• C. glabrata accounts for 10-20% of recurrent vulvovaginal candidiasis cases and requires "complicated" treatment protocols distinct from C. albicans, according to the Centers for Disease Control and Prevention guidelines 10
• The Centers for Disease Control and Prevention recommends obtaining vaginal cultures to confirm C. glabrata, as microscopy cannot reliably identify this species 10
• Oil-based vaginal preparations may weaken latex condoms and diaphragms, risking contraceptive failure, as noted by the Centers for Disease Control and Prevention 10
• Partner treatment is not routinely recommended, as vulvovaginal candidiasis is not sexually transmitted, according to the Centers for Disease Control and Prevention 10
• Male partners with symptomatic balanitis may benefit from topical antifungal therapy, as suggested by the Centers for Disease Control and Prevention 10
• Non-fluconazole azole drugs for 7-14 days can be attempted, though conventional azole therapies are less effective against C. glabrata than C. albicans, as reported by the Centers for Disease Control and Prevention 10
• Avoid fluconazole monotherapy for confirmed C. glabrata, as it is ineffective at standard doses, according to the Centers for Disease Control and Prevention 10

Management of Candida glabrata Vulvovaginal Infection

Diagnostic Confirmation

First‑Line Therapy

Agents to Avoid

Alternative Treatment Options (when boric acid is unavailable or fails)

Treatment Duration and Monitoring

Special Considerations

Maintenance Therapy for Recurrent Infection

Epidemiology and Resistance

Patients with Diabetes or on Corticosteroids

First‑Line and Alternative Therapies for Vaginal Candida glabrata Infection

Epidemiology and Resistance

• Candida glabrata accounts for 10 %–20 % of recurrent vulvovaginal candidiasis cases and exhibits intrinsic reduced susceptibility to standard‑dose azole antifungals, classifying the condition as “complicated” vulvovaginal candidiasis. 13

Diagnostic Confirmation

• Wet‑mount microscopy with 10 % potassium hydroxide can demonstrate yeast cells but cannot reliably differentiate C. glabrata from other yeasts; culture is required for definitive species identification. 13
• Vaginal pH should be 4.0–4.5; values above this range suggest alternative etiologies such as bacterial vaginosis or trichomoniasis. 13

First‑Line Therapy (Infectious Diseases Society of America)

• Intravaginal boric acid 600 mg in a gelatin capsule, administered once daily for 14 days, is strongly recommended (low‑quality evidence) as the primary treatment, especially after azole failure or when azole resistance is suspected. 14
• The boric‑acid formulation must be compounded by a pharmacist to produce vaginal‑compatible gelatin capsules. 13

Alternative Regimens (When Boric Acid Is Unavailable or Not Tolerated)

• Nystatin vaginal suppositories 100,000 units daily for 14 days receive a strong recommendation (low‑quality evidence) as an alternative option. 14
• Topical 17 % flucytosine cream, alone or combined with 3 % amphotericin B cream, administered daily for 14 days, carries a weak recommendation (low‑quality evidence) for azole‑refractory C. glabrata infection. [13][14]

Special Populations

• HIV‑positive women have identical response rates to treatment as HIV‑negative women; therefore, the therapeutic approach should not differ based on HIV status. 15